IPHA vs. ABOS, OPT, ELEV, CRDF, KOD, IPSC, CMPX, XFOR, PSTX, and GRPH
Should you be buying Innate Pharma stock or one of its competitors? The main competitors of Innate Pharma include Acumen Pharmaceuticals (ABOS), Opthea (OPT), Elevation Oncology (ELEV), Cardiff Oncology (CRDF), Kodiak Sciences (KOD), Century Therapeutics (IPSC), Compass Therapeutics (CMPX), X4 Pharmaceuticals (XFOR), Poseida Therapeutics (PSTX), and Graphite Bio (GRPH). These companies are all part of the "biological products, except diagnostic" industry.
Innate Pharma (NASDAQ:IPHA) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, community ranking, analyst recommendations, dividends, earnings and institutional ownership.
Innate Pharma's return on equity of 0.00% beat Acumen Pharmaceuticals' return on equity.
0.2% of Innate Pharma shares are owned by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. 31.9% of Innate Pharma shares are owned by insiders. Comparatively, 7.5% of Acumen Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
In the previous week, Innate Pharma had 3 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 6 mentions for Innate Pharma and 3 mentions for Acumen Pharmaceuticals. Acumen Pharmaceuticals' average media sentiment score of 0.83 beat Innate Pharma's score of 0.42 indicating that Acumen Pharmaceuticals is being referred to more favorably in the news media.
Innate Pharma received 20 more outperform votes than Acumen Pharmaceuticals when rated by MarketBeat users. However, 64.29% of users gave Acumen Pharmaceuticals an outperform vote while only 54.29% of users gave Innate Pharma an outperform vote.
Innate Pharma currently has a consensus target price of $9.75, indicating a potential upside of 306.25%. Acumen Pharmaceuticals has a consensus target price of $12.25, indicating a potential upside of 253.03%. Given Innate Pharma's higher possible upside, analysts clearly believe Innate Pharma is more favorable than Acumen Pharmaceuticals.
Innate Pharma has higher revenue and earnings than Acumen Pharmaceuticals.
Innate Pharma has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500. Comparatively, Acumen Pharmaceuticals has a beta of 0.08, suggesting that its stock price is 92% less volatile than the S&P 500.
Summary
Innate Pharma beats Acumen Pharmaceuticals on 9 of the 13 factors compared between the two stocks.
Get Innate Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for IPHA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IPHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Innate Pharma Competitors List
Related Companies and Tools
